Systematic review of psychosocial outcomes for patients with advanced melanoma

Dunn, Jeff, Watson, Maggie, Aitken, Joanne F. and Hyde, Melissa K. (2016) Systematic review of psychosocial outcomes for patients with advanced melanoma. Psycho-Oncology, 26 11: 1722-1731. doi:10.1002/pon.4290

Author Dunn, Jeff
Watson, Maggie
Aitken, Joanne F.
Hyde, Melissa K.
Title Systematic review of psychosocial outcomes for patients with advanced melanoma
Journal name Psycho-Oncology   Check publisher's open access policy
ISSN 1099-1611
Publication date 2016-11-07
Sub-type Article (original research)
DOI 10.1002/pon.4290
Open Access Status Not yet assessed
Volume 26
Issue 11
Start page 1722
End page 1731
Total pages 10
Place of publication Chichester, West Sussex, United Kingdom
Publisher John Wiley & Sons
Language eng
Abstract New advanced melanoma therapies are associated with improved survival; however, quality of survivorship, particularly psychosocial outcomes, for patients overall and those treated with newer therapies is unclear.

Synthesize qualitative and quantitative evidence about psychosocial outcomes for advanced (stage III/IV) melanoma patients.

Five databases were searched (01/01/1980 to 31/01/2016). Inclusion criteria were as follows: advanced melanoma patients or sub-group analysis; assessed psychosocial outcomes; and English language.

Fifty-two studies met review criteria (4 qualitative, 48 quantitative). Trials comprise mostly medical not psychosocial interventions, with psychosocial outcomes assessed within broader quality of life measures. Patients receiving chemotherapy or IFN-alpha showed decreased emotional and social function and increased distress. Five trials of newer therapies appeared to show improvements in emotional and social function. Descriptive studies suggest that patients with advanced, versus localized disease, had decreased emotional and social function and increased distress. Contributors to distress were largely unexplored, and no clear framework described coping/adjustment trajectories. Patients with advanced versus localized disease had more supportive care needs, particularly amount, quality, and timing of melanoma-related information, communication with and emotional support from clinicians. Limitations included: lack of theoretical underpinnings guiding study design; inconsistent measurement approaches; small sample sizes; non-representative sampling; and cross-sectional design.

Quality trial evidence is needed to clarify the impact of treatment innovations for advanced melanoma on patients' psychosocial well-being. Survivorship research and subsequent translation of that knowledge into programs and services currently lags behind gains in the medical treatment of advanced melanoma, a troubling circumstance that requires immediate and focused attention.
Keyword Advanced melanoma
Metastatic melanoma
Supportive care
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ
Additional Notes Published online 7 November 2016

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Social Science Publications
Version Filter Type
Citation counts: Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 01 Aug 2017, 00:11:40 EST by System User on behalf of Learning and Research Services (UQ Library)